创下2024年以来最大规模生物科技IPO,纳斯达克上市募资4亿美元
Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing
生物技术与制药领域的最新动态
Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing
Thermo Fisher unveils test to aid in dosing of antirejection drug
Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN - MarketBeat
Agilent Technologies, Inc. $A Shares Sold by Primecap Management Co. CA - MarketBeat
Goldman Sachs Adjusts Price Target on Agilent Technologies to $150 From $170, Maintains Buy Rating - marketscreener.com
Intech Investment Management LLC Buys Shares of 41,208 Waters Corporation $WAT - MarketBeat
TD Asset Management Inc Raises Stock Holdings in Waters Corporation $WAT - MarketBeat
Thermo Fisher unveils test to aid in dosing of antirejection drug - Fierce Biotech
Erste Asset Management GmbH Trims Stock Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat
Thermo Fisher Scientific Stock To $390? - Trefis
Decoding Thermo Fisher Scientific Inc (TMO): A Strategic SWOT In - GuruFocus
Here’s What Analysts Think About Thermo Fisher Scientific (TMO) Post Earnings - Yahoo Finance
Assessing Illumina (ILMN) Valuation After Recent Share Price Momentum Shifts - simplywall.st
Spatial Biomarker Panels for Clinical Trials
Generate caps a strong month for biotech IPOs with $400M offering
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics - The Korea Herald
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
Agilent Technologies (A) Margin Slippage Challenges Bullish Earnings Improvement Narrative - simplywall.st